Amplia Therapeutics says fresh preclinical findings support its drug development efforts for hard-to-treat pancreatic and ovarian cancers. Across reports, the company highlights new laboratory data for narmafotinib, its pancreatic cancer drug candidate. Amplia states the results suggest the candidate can target multiple biological drivers involved in the progression of the disease. The coverage notes that the company is using the data to back its ongoing research and related therapeutic strategy, positioning narmafotinib as a potential treatment approach given the complexity of the cancers it is aimed at. While the articles focus on the preclinical stage of the work, they do not report any clinical trial outcomes or regulatory decisions. The reporting is largely consistent in describing the same company claim: that the newly presented preclinical evidence indicates narmafotinib acts on several disease-relevant targets, strengthening Amplia’s rationale for continued development.